Nova Eye Medical Limited (ELXMF) Announces Record Q2 2026 Sales and Strategic Outlook After Investor Call

January 19, 2026 — Nova Eye Medical Limited (OTC: ELXMF), a leading medical technology company specializing in innovative ophthalmic devices, reported exceptionally strong sales results for the second quarter of its fiscal year 2026 during an investor sales and trading call held on January 18, 2026. The company highlighted record revenue performance, expanding market adoption of its glaucoma device portfolio and an optimistic outlook for the year ahead.

Overview of the Q2 2026 Sales and Trading Call

Nova Eye Medical’s quarterly sales and trading call offered investors and analysts insights into the company’s operating performance for the period ending December 31, 2025 — corresponding to the second quarter of its 2026 fiscal year. The call was hosted by Mark Flynn, Head of Investor Relations, and Thomas Spurling, Managing Director and Executive Director of the company.

During the call, company leadership emphasized that the quarter delivered record sales results driven by strong demand for Nova Eye Medical’s flagship interventional glaucoma devices, particularly iTrack Advance and Molteno3. These devices are designed to improve patient outcomes and reduce reliance on traditional glaucoma medications.

Record Quarterly Results

Nova Eye Medical reported that the quarter ending December 31, 2025 was the best in the company’s history in terms of sales volume and revenue growth compared with prior quarters. While specific dollar figures were not disclosed in the public Seeking Alpha summary, the leadership highlighted that performance was ahead of internal expectations and demonstrated strong scaling of commercial operations across key markets.

In his opening remarks, Mark Flynn noted:

"We are proud to report a record quarter for Nova Eye Medical. Our performance highlights underscore the strength of our products, the depth of clinical adoption, and the strategic investments we have made in expanding our global footprint."

Management Commentary: Market Dynamics and Strategic Positioning

Thomas Spurling, Managing Director, provided a comprehensive overview of market dynamics and the company’s strategic direction during his presentation on the call. He emphasized the growing interventional glaucoma market, which seeks to alter the disease course earlier in its progression through surgical intervention rather than relying solely on pharmacological treatment.

Spurling outlined the broader challenges in glaucoma care, noting that traditional pharmaceutical therapies — while effective for managing pressure — often result in poor quality-of-life outcomes for patients due to side effects or the burden of daily drop regimens. In contrast, interventional surgical technologies like Nova Eye Medical’s devices aim to improve long-term outcomes and reduce dependence on chronic medication.

Interventional Glaucoma Opportunity

Interventional glaucoma treatment has grown in importance as healthcare professionals seek advanced solutions to slow disease progression and improve patient quality of life. Devices such as iTrack Advance are minimally invasive and designed to enhance the eye’s natural drainage pathways to help control intraocular pressure — the primary risk factor for glaucoma damage.

According to Spurling, the global shift toward earlier surgical engagement has benefited companies that can demonstrate clinical efficacy, operational scalability, and improved long-term outcomes. “Our focus remains on ensuring that ophthalmic surgeons have access to reliable and effective tools that enable better patient outcomes and reduce dependency on medications,” he said.

Business Highlights and Product Portfolio

During the call, management took the opportunity to highlight Nova Eye Medical’s diversified product portfolio and recent commercial achievements, reinforcing the company’s role as an innovator in glaucoma treatment. The core of Nova Eye Medical’s offering includes the minimally invasive iTrack Advance and the drainage-focused Molteno3 devices.

iTrack Advance: Expanding Adoption

iTrack Advance is engineered to address mild to moderate open-angle glaucoma by restoring natural fluid outflow without cutting or damaging tissue. Its adoption by eye surgeons globally has been cited as a key driver of the recent sales increase. The device’s minimally invasive nature has made it an attractive option for both patients and physicians looking to preserve vision with fewer complications.

Spurling underscored that broader clinical acceptance in key regions, including the United States, Europe, and Australia, contributed significantly to the revenue growth achieved this quarter. Additionally, he noted that ongoing clinical data supporting iTrack Advance’s performance continues to foster confidence among practitioners.

Molteno3: Addressing Severe Glaucoma Needs

The Molteno3 glaucoma drainage device targets patients with more advanced disease stages, where pressure control is critical to prevent further optic nerve damage. The company reported that Molteno3 sales also contributed notably to the quarter’s record results due to increased surgical utilization and broader market penetration.

Nova Eye Medical’s diversified approach — offering solutions for both mild/moderate and severe glaucoma cases — positions it advantageously in a market where patient needs vary widely based on disease progression.

Geographic Expansion and Market Penetration

Management emphasized that geographic expansion played a key role in the strong Q2 performance. The company’s strategic investments in sales infrastructure, distributor relationships, and clinical education programs have expanded its reach in high-growth regions.

Particularly noteworthy was the expansion of commercial operations in North America, where the demand for innovative glaucoma interventions remains robust. Nova Eye Medical’s ability to scale distribution — while maintaining high satisfaction among clinical partners — was cited as a major contributor to the sales uplift.

Clinician Training and Education Initiatives

In addition to sales growth, Nova Eye Medical highlighted its clinician training and education initiatives, which aim to accelerate adoption of its technologies. By hosting workshops and partnering with leading eye centers, the company supports surgeons in mastering its devices and incorporating them into regular practice.

This strategic emphasis on education not only boosts product utilization but also strengthens long-term relationships with key opinion leaders in the ophthalmic community, which management believes will underpin sustained growth.

Management’s Outlook for the Remainder of Fiscal 2026

Looking ahead, Nova Eye Medical’s leadership shared an optimistic outlook for the remainder of fiscal year 2026. While acknowledging competitive and regulatory challenges, the company emphasized its strong pipeline of clinical data and its commitment to enhancing shareholder value through disciplined execution.

Tom Spurling noted that the company plans to focus on several strategic priorities:

• Strengthening Distribution Channels: Continue expanding partnerships with distributors and strategic commercial allies in key markets.
• Enhancing Reimbursement Coverage: Work with healthcare systems and payers to improve reimbursement terms for interventional glaucoma procedures.
• Launching New Clinical Studies: Support additional studies that demonstrate long-term effectiveness and safety profiles of core devices.

These efforts, according to management, are intended to solidify Nova Eye Medical’s competitive position and sustain momentum in both developed and emerging markets.

Investor Engagement and Market Response

Investor response to the Q2 sales announcement and subsequent call was generally positive, with increased interest in the company’s strategy and market potential. Prior to the call, Nova Eye Medical had scheduled an investor webinar to deliver its half-year sales update, underscoring its commitment to transparency and engagement with shareholders.

Market analysts tracking ELXMF have noted the company’s progress within the context of the broader ophthalmic device sector. While the stock has been subject to typical small-cap volatility, the recent performance has reinforced confidence in the company’s growth trajectory.

About Nova Eye Medical Limited

Nova Eye Medical Limited is a global medical technology company focused on developing, manufacturing and commercializing advanced devices for the treatment of glaucoma — a leading cause of irreversible blindness worldwide. The company’s products aim to improve clinical outcomes and quality of life for patients by offering minimally invasive and effective alternatives to traditional therapies.

The company’s portfolio includes:

• iTrack Advance: A minimally invasive surgical device for mild to moderate glaucoma.
• Molteno3 Glaucoma Drainage Device: A device used in more advanced glaucoma cases to improve long-term pressure control.

Nova Eye Medical operates globally with commercial and distribution networks supported by clinical education initiatives and ongoing product development.

Conclusion: Strong Quarter Sets Stage for Continued Growth

Nova Eye Medical’s Q2 2026 sales and trading call highlighted the company’s record performance, driven by growing adoption of its glaucoma treatment technologies and expanding global reach. With a strategic focus on clinician engagement, distribution expansion, and ongoing clinical validation, management is positioning the company for sustained growth throughout the remainder of the fiscal year and beyond.

This positive momentum reflects the potential of Nova Eye Medical to play an increasingly significant role in the interventional glaucoma market, delivering value to both patients and investors.

#NovaEyeMedical #GlaucomaTreatment #ELXMF #MedicalDevices #SlimScan #GrowthStocks #CANSLIM